Truist Securities Reiterates Immunovant (IMVT) at Buy, $12 PT, Sees batoclimab Peak Sales of $430M Across Two Indications
Tweet Send to a Friend
Truist Securities analyst Robyn Karnauskas reiterated a Buy rating and $12.00 price target on Immunovant (NASDAQ: IMVT)The analyst comments: "We ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
